JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

A REVIEW ON NATIONAL & INTERNATIONAL SCENARIO OF PHARMACOVIGILANCE

AJAY KUMAR , POOJA RAO, ANKITA RAIKWAR3

M. Pharm, M. Pharm, Assistant Professor

Jaipur National University

ABSTRACT:

Review includes PvPI(Pharmacovigilance Programme of India) illustration that is used to protect the population's health particularly in India by ensuring advantages of using a medicine that outweighs any hazards. Significant social and economic costs associated with adverse drug reactions and favourable benefit-to-cost ratio of implementing appropriate risk management, it is necessary to involve both the general public and healthcare professionals in a well-organized programme to create synergies for tracking adverse drug reactions across the nation. This review basically involves discussion and analysis about current situation and future of PV(Pharmacovigilance) in India as well as globally. Pharmacovigilance legislation aims to reduce number of Adverse Reactions (ADRs) and is achieved by collection of better data on medicines and their safety. Rapid and robust assessment of issues related to safety of medicines, effective regulatory action to deliver safe and effective use of medicines, empowerment of patients through reporting and participation, increased levels of transparency and better communication aims to strengthen the Pharmacovigilance status in India.

KEY WORDS: Pharmacovigilance, Adverse drug reaction, PvPI, EU, MHRA.

Introduction:

Pharmacovigilance officially came into existance in 1961, WHO in 1968 promoted the ‘Programme for International Drug Monitoring’ a pilot project that aimed to centralize world data on Adverse Drug Reactions (ADRs) [1, 2]. In particular, the main aim of the “WHO Programme” is to identify the earliest possible PV signals. PV was proposed in the mid-70s by a French group of pharmacologists and toxicologists to define the activities promoting ‘The assessment of the risks of side effects potentially associated with drug treatment’. According to WHO PV is ‘the pharmacological science relating to the detection, assessment, understanding, and prevention of ADRs, particularly long-term and short-term ADRs of medicines, PV serves various roles

such as identification, quantification, and documentation of drug-related problems which are responsible for drug-related injuries.

Pharmacovigilance is basically pharmacological science relating to detection, assessment, understanding, and prevention of adverse effects, particularly long-term and short-term adverse effects of medicines. Pharmacovigilance is important and integral part of clinical research. Both, the safety of clinical treasonous-marketing pharmacovigilance is critical throughout the product lifecycle. With several recent high-profile drug withdrawals, like Cerivastatin, the pharmaceutical industry and regulatory agencies have raised the issue of pharmacovigilance. Early detection of signals from both clinical trials and post-marketing surveillance studies have now been adopted by major pharmaceutical companies to identify the risks associated with the medicinal product and effective management of risks by applying robust risk management plans throughout the life cycle of the product. Signal detection and risk management have added a new dimension to the field of pharmacovigilance and as an evolving discipline, it requires ongoing refinement to increase its applicability and value to public health. While major advancements in the discipline of pharmacovigilance have taken place, but not much has been achieved in India. However, with more clinical trials and clinical research activity being conducted in India, there is an immense need to understand the importance of pharmacovigilance and how it impacts the lifecycle of the product. It will enable the integration of good pharmacovigilance practice in the processes and procedures to help ensure regulatory compliance and enhance clinical trial safety and post-marketing surveillance.

WHO characterized pharmacovigilance as “the science and exercises identifying with the identification, appraisal, comprehension and counteractive action of antagonistic impacts or some other medication-related issue”. It is a vital and indistinguishable piece of clinical research. Both clinical preliminary safety and post-showcasing pharmacovigilance (regularly known as Post promoting studies or Phase IV clinical preliminaries) is essential through item life cycle. With a sensibly high number of late prominent medication withdrawals, both the pharmaceutical business and in addition different administrative offices over the globe have expanded the bar. Early identification from the post-advertising observation and clinical preliminaries in early stages have now been adjusted by significant pharmaceutical organizations to recognize the dangers related to their therapeutic item on time .An ADR is characterized by the WHO as “a toxic, unexpected impact of a medication that happens in portions regularly utilized in people for the conclusion, prophylaxis, and treatment of ailment”.

The National Pharmacovigilance Program and the Pharmacovigilance Program of India are the most recent advancements in this field in the country. The USA and Europe have well-established PV systems in place thanks to technological progress and other resources. India is the largest producer of pharmaceuticals in the world and a major clinical research hub; hence, it requires a more stringent PV setup. With the increase in population and novel drugs in the market each day, there is a need for an effective PV system in India.

A new drug in research and development is subjected to all tests, including preclinical studies and clinical trials, before being released into the market. ADRs are caused by a variety of factors, including age, gender, genetic factors, food habit patterns, coexisting co-morbidities, geographical variations, and concomitant medications.

With more clinical trials and clinical research activity being conducted in India, there is an immense need to understand the importance of pharmacovigilance and how it impacts the lifecycle of the product. This will enable the integration of good pharmacovigilance practice in the processes and procedures to help ensure regulatory compliance and enhance clinical trial safety and post-marketing surveillance.

PV is the science of collecting, monitoring, researching, assessing, and evaluating information from healthcare providers and patients on the adverse effects of medications, biological products, blood products, herbals, vaccines, medical devices, and traditional and complementary medicines to identify new information about hazards associated with products and preventing harm to patients. The challenge of maximizing drug safety and maintaining public confidence has become increasingly complex. Pharmaceutical and biotechnology companies must not only monitor but also proactively estimate and manage drug risk throughout product lifecycle, from development to post-market survelliance.

PHARMACOVIGILANCE PROGRAM OF INDIA

The Central Drugs Standard Control Organization (CDSCO), New Delhi, under the aegis of the Ministry of Health & Family Welfare, Government of India initiated a nationwide Pharmacovigilance program in July 2010. The Pharmacovigilance Program of India (PvPI) was launched with the broad objective of safeguarding the health of billions of people in India. Adverse Drug Reactions (ADRs) are reported from all over the country to the National Coordination Centre (NCC)-PvPI, which also works in collaboration with the global ADR monitoring center (WHOUMC), in Sweden, to contribute to the global ADR database. NCC-PvPI monitors the ADRs among the Indian population and helps the regulatory authorities of India (CDSCO, Indian Pharmacopeia Commission (IPC)) in deciding on the safe use of medicines. PvPI collects and evaluates spontaneous reports of Adverse Drug Reactions (ADRs) due to the use of medicines, vaccines, medical devices, and herbal products from all healthcare professionals and consumers/patients. To monitor ADRs and report the same to NCC PvPI, ADR Monitoring Centers (AMCs) have been set up all over India. At present 250 AMCs (medical colleges, district, and corporate hospitals, etc.) are enrolled under PvPI across the country.

PROGRAMME IS INTENDED IN FOUR PHASES:

Beginning (2010– 2011); expansion and consolidation (2011–2012); expansion and maintenance (2012–2013); expansion and optimization (2013–2014); and excellence (2014– 2015); and herein evolving since now. Additionally, the programme has three expert panels (quality review, signal review, and core training panels) that provide technical advice to the regulatory and a steering committee and working group that provides technical input to the regulatory.

(1) The Quality Review Panel evaluates the accuracy and completeness of ICSRs, offers suggestions to the PvPI working group following data analysis, and creates formats and instructions for subsequent activities.

(2) The Signal Review Panel specifies biostatistical methodologies for analysis and actionable indicators, detects and assesses signals from the ICSRs provided to NCC, and recommends to CDSCO the necessary regulatory responses.

(3) The Core Training Panel works with foreign organizations regarding involvement in the implementation of pharmacovigilance training programs as well as recognizes trainers, training needs, and training material

(4) Adverse Reactions Monitoring Centers spread throughout both private hospitals and medical universities with teaching hospitals linked to them.

However, what needs to be more important along with the funding is a focused vision and effective strategy for developing the pharmacovigilance systems, especially in the Drug Controller General of India Office, which is lacking. Because of not that much awareness about pharmacovigilance in pharmaceuticals, there is immense shortage of knowledgeable people who will be able to advise the DCGI on this matter, as pharmacovigilance is a very complex subject, intertwined with regulations and complex systems. The need is therefore to engage a completely independent adviser who has extensive and practical knowledge of pharmacovigilance, who can act as Pharmacovigilance Advisor to the Government of India to effectively implement the systems and policies on pharmacovigilance. This will help the DCGI to spearhead the activities and implementation of pharmacovigilance. The information obtained to date in the zonal centers from various peripheral centers is often poor and not well-analyzed. There is insufficient research on ADRs in India, so the exact incidence of specific ADRs is unknown. The reporting forms used by many people engaged in various pharmacovigilance work are different from the reporting forms used by the National Pharmacovigilance Program, which makes it extremely difficult to transfer data to the national database, even if this has been shared by the various parties. Understanding by healthcare professionals (both in rural areas and urban cities and hospitals) and knowledge and motivation for pharmacovigilance are almost negligible. There is hardly any encouragement from the Department of Health to provide more training and create more awareness amongst them for better reporting. In India, several consumer groups encourage patients to report any adverse reactions encountered by them, although there is no information for patients on how to report ADRs directly to the regulatory authority. Direct reports from the patients, the ones who experience ADRs, are not accepted by the monitoring centers and regulatory authorities.

CURRENT SCENARIO OF PHARMACOVIGILANCE IN INDIA

India is a vast country and there is a surfeit of drug brands, n number of licensed drug manufacturers and branded formulations. India is the fourth largest producer of pharmaceuticals in the world and is also emerging as a hub for clinical trials. Many new drugs are being introduced in the country, so there is an immense need to improve the pharmacovigilance system to protect the Indian population from potential harm that may be caused by some of the new drugs. In the past, India's regulatory agencies and drug companies based on their safety assessments on experiences derived from long-term drug use in the Western markets concluded no real urgency for the government to establish a strong pharmacovigilance system of its own. In recent years, however, the lag between when a drug is placed in the market and its subsequent availability in India has decreased considerably so that the much-needed longer-term safety data is no longer available. In addition, India-based drug companies have increased their capacity to develop and launch new drugs through their research efforts and this has heightened the importance of developing adequate internal pharmacovigilance standards to detect adverse drug events[7]. However, what needs to be more important along with the funding is a focused vision and effective strategy for developing the pharmacovigilance systems, especially in the Drug Controller General Of India Office, which is lacking. Traditionally, pharmacovigilance was never done in India in pharmaceutical companies, be it Indian or multinational companies (MNCs), so there is an immense shortage of knowledgeable people who will be able to advise the DCGI on this matter, as pharmacovigilance is a very complex subject, intertwined with regulations and complex systems. The need is therefore to engage a completely independent adviser who has extensive and practical knowledge on pharmacovigilance, who can act as a Pharmacovigilance Advisor to the Government of India to effectively implement the systems and policies on pharmacovigilance.

In India, several consumer groups encourage patients to report any adverse reactions encountered by them, although there is no information for patients on how to report ADRs directly to the regulatory authority. Direct reports from the patients, the ones who experience ADRs, are not accepted by the monitoring centers and regulatory authorities. To add to this is the total lack of awareness about ADRs in the general population. With more and more clinical trials and other clinical research activities being conducted in India, there is an immense need to understand the importance of pharmacovigilance and how it impacts the lifecycle of the product. Given this situation at present, the DCGI should act quickly to improve pharmacovigilance to integrate Good Pharmacovigilance Practice into the processes and procedures to help ensure regulatory compliance and enhance clinical trial safety and post-marketing surveillance.

PHARMACOVIGILANCE IN PHARMACEUTICAL INDUSTRIES

The aims of pharmacovigilance within the industry is essentially to protect patients from unnecessary harm by identifying previously unrecognized drug hazards, elucidating pre-disposing factors, refusing false safety signals, and quantifying risk about benefit.

WORLDWIDE MONITORING OF PHARMACOVIGILANCE

Enrollment of the WHO for International Drug Monitoring is facilitated by WHO Collaborating Center for International Drug Monitoring, known as the UMC(Uppsala Monitoring Centre). Pharmacovigilance presently dependent on sound logical standards and is basic to successful clinical practice.

Scope of accomplishment of PV medication safety checking-

a) The Quality Assurance and Safety: Department of Essential Drugs and Medicines Policy (WHO), Sweden deals with universal database of ADR reports from world.
b) The National Pharmacovigilance Centers: aims their attention to tranquilize safety.
c) Hospitals: various medicinal foundations have progressed ADRs and drug blunder close watch frameworks in their centers and wards.
d) Academia: focuses of pharmacology and drug store that have important role in instructing, preparing, assessing, strategy improvement, clinical research, morals councils (institutional survey sheets) and the clinical administrations.
e) Health Professionals: Physician being the experts to report ADR by practicing the aptitude of differential determination.
f) Patients: Coordinate patient councelling investment in identifying medication-related issues.

RESULT

Pharmacovigilance fundamentally comprises the safety of prescription being the integral part of the drug regulation system that involves indispensable role in the identification, assessment, and publicizing of adverse drug reactions. Drug specialists have entered jobs in wellbeing frameworks to keep up the objective and safe utilization of medication for they are sedate specialists who are unequivocally prepared in this field. Reconciliation of ADR detailing ideas in instruction educational programs, preparing of drug specialists and willful commitment of drug specialists in ADR announcing is essential in accomplishing the safety objectives and preservation of general wellbeing. Without adequately recognizing and acknowledging preparing requirements of drug specialists and other social insurance experts, the ability of national pharmacovigilance frameworks is probably not going to enhance which may trade off patient safety.

ADRs account for serious harm to the patients and even lead to morbidity and mortality. The PV databases help in the promotion of safe drug use and protection of public health safety. This review article compares the PV system in the USA, Europe, and India, highlighting the challenges and future perspectives to be adapted to widen the horizon of the existing PV structure in India. The National Pharmacovigilance Program and the Pharmacovigilance Program of India are the most recent advancements . India is the largest producer of pharmaceuticals in the world and a major clinical research hub; hence, it requires a more stringent PV setup. With the increase in population and novel drugs in the market each day, there is a need for an effective PV system in India. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) has elaborated a pharmacovigilance guideline for medicines approved in the U.S., the E.U., and Japan. Moreover, these systems use a common methodology, based on a regulatory body, post-marketing surveillance, risk management, post-approval research, and enforcement.

CONCLUSION

Being drug masters and coaches of sheltered and compelling medication use, pharmacists have critical pretend in the identification, reporting, observing alongside avoidance of ADRs. The absence of anxiety still exists among pharmacists who are restricted to change from item situated to patient arranged. Strengthening and commitment of network pharmacists to patient record checks and electronic announcing will likewise reduce ADR-related occasions.

India is now considered to be a hub for clinical research. The DCGI has shown its commitment to ensuring the safe use of drugs by establishing the National Pharmacovigilance Program. More and more clinical trials are now being conducted in India and business process outsourcing (BPOs) based in India are now also undertaking pharmacovigilance projects from MNCs. Healthcare professionals, consumer groups, NGOs, and hospitals should appreciate that there is now a system in place to collect and analyze adverse event data. They should start reporting adverse events actively and participate in the National Pharmacovigilance Program to help ensure that people in India receive safe drugs. With the help and proper coordination of all stakeholders, we can build a world-class pharmacovigilance system in India.

REFERENCE:

1. Sheltie SA, Limaye RP. An evaluation of knowledge, attitude, and perception about adverse drug reactions and pharmacovigilance among postgraduate students in a Medical College Teaching Hospital of Sangli. National Journal of Physiology, Pharmacy and Pharmacology. 2022;12(2):121-6.
2. Pant J, Marwah H, Singh RM, Hazra S. An overview of the worldwide master key for pharmacovigilance and its role in India. Journal of Pharmacovigilance and Drug Research. 2021 Jun 1;2(2):19-26.
3. World Health Organization. Medication safety in polypharmacy: technical report. World Health Organization; 2019.

4. Nimesh S, Ashwlayan VD. Pharmacovigilance: an overview. Int. J. Pharmacovigilance. 2018;3 (1).
5. Beninger P. Pharmacovigilance: an overview. Clinical therapeutics. 2018 Dec 1;40(12):1991- 2004.
6. Lihite RJ, Lahkar M. An update on the pharmacovigilance programme of India. Frontiers in pharmacology. 2015 Sep 22;6:194.
7. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998 Apr 15;279(15):1200-5.
8. Mandal SC, Mandal M. Evolution of pharmacovigilance programme: Present status in India. Pharma times. 2017;49(5):31-6. [10] Thomas KB. Chloroform: commissions and omissions. [11] Vakil BJ, Kulk
9. WHO Definition of Pharmacovigilance. 2002.
10. Manual for Good Bioavailability and Bioequivalence Practices. Vol. 1, Mod. 1. Clinical Phase. 1st ed. Brazil; 2002. p. 5-6. Available from: [Last accessed on 2010 Aug 25].
11. Kulkarni RD. Reporting system for rare side effects of non-narcotic analgesics in India: Problems and opportunities. Med Toxicol1986;1:110-3.
12. Protocol for National Pharmacovigilance Program. CDSCO, Ministry of Health and Family Welfare, Government of India, 2004.
13. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998;279:1200-5.
14. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. N Engl J Med 2003;348:1556- 64.
15. Nair MD. Pharmacovigilance: The need for a formal system in India. Available from: http://www.pharmabiz.com. [Last accessed on 2010 Aug 25].
16. The Erice declaration: On communicating drug safety information. Prescrire Int 1998;7:191.
17. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union 30 April 2004: L136/34-L 136/57.
18. AlDweik R, Stacey D, Kohen D, Yaya S. Factors affecting patient reporting of adverse drug reactions: a systematic review. Br J Clin Pharmacol. 2016;83(4):875-83.
19. . Gurmesa LT, Dedefo MG. Factors Affecting Adverse Drug Reaction Reporting of Healthcare Professionals and Their Knowledge, Attitude and Practice towards ADR Reporting in Nekemte Town, West Ethiopia. Biomed Res Int. 2016;2016.
20. Avong YK, Jatau B, Gurumnaan R, et al. Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/ AIDS, Tuberculosis and Malaria: A prospective cohort study. PLoS One. 2018;13(8):e0200810. DOI: 10.1371/journal.pone.0200810

21. . O'Callaghan J, Griffin BT, Morris JM, Bermingham M. Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland. Bio Drugs. 2018;32(3):267-80.
22. Hohl CM, Small SS, Peddie D, Badke K, Bailey C, Balka E. Why Clinicians Don't Report Adverse Drug Events: Qualitative Study. JMIR Public Health Surveill. 2018;4(1):e21. doi:10.2196/publichealth.9282
23. Gifford ML, Anderson JE. Barriers and motivating factors in reporting incidents of assault in mental health care. J Am Psychiatr Nurses Assoc. 2010;16(5):288- 98. doi: 10.1177/1078390310384862. PubMed PMID: 21659279.
24. . Ferner RE, Easton C, Cox AR. Deaths from Medicines: A Systematic Analysis of Coroners' Reports to Prevent Future Deaths. Drug Saf. 2018;41(1):103-10. doi: 10.1007/s40264-017-0588-0. PubMed PMID: 28808959
25. Giardina C, Cutroneo PM, Mocciaro E, et al. Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. Front Pharmacol. 2018;9:350. doi:10.3389/ fphar.2018.00350
26. Chu DK, Kim LH, Young PJ, Zamiri N, Almenawer SA, Jaeschke R, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018;391(10131):1693-705. doi: 10.1016/S0140-6736(18)30479-3. PubMed PMID:29726345.